Stock Research for ARQL

ARQL
Current Price

$1.7300


Latest Update: 2018-02-16 16:00:00

High
$ 1.7500
Low
$ 1.7200
Close
$ 1.7200
Volume
2718
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ARQL Stock Chart & Research Data

The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARQL Due diligence Resources & Stock Charts

The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARQL Detailed Price Forecast - CNN Money CNN View ARQL Detailed Summary - Google Finance
Yahoo View ARQL Detailed Summary - Yahoo! Finance Zacks View ARQL Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ARQL Trends & Analysis - Trade-Ideas Barrons View ARQL Major Holders - Barrons
NASDAQ View ARQL Call Transcripts - NASDAQ Seeking View ARQL Breaking News & Analysis - Seeking Alpha
Spotlight View ARQL Annual Report - CompanySpotlight.com OTC Report View ARQL OTC Short Report - OTCShortReport.com
TradeKing View ARQL Fundamentals - TradeKing Charts View ARQL SEC Filings - Bar Chart
WSJ View Historical Prices for ARQL - The WSJ Morningstar View Performance/Total Return for ARQL - Morningstar
MarketWatch View the Analyst Estimates for ARQL - MarketWatch CNBC View the Earnings History for ARQL - CNBC
StockMarketWatch View the ARQL Earnings - StockMarketWatch MacroAxis View ARQL Buy or Sell Recommendations - MacroAxis
Bullish View the ARQL Bullish Patterns - American Bulls Short Pains View ARQL Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ARQL Stock Mentions - StockTwits PennyStocks View ARQL Stock Mentions - PennyStockTweets
Twitter View ARQL Stock Mentions - Twitter Invest Hub View ARQL Investment Forum News - Investor Hub
Yahoo View ARQL Stock Mentions - Yahoo! Message Board Seeking Alpha View ARQL Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ARQL - SECform4.com Insider Cow View Insider Transactions for ARQL - Insider Cow
CNBC View ARQL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARQL - OTC Markets
Yahoo View Insider Transactions for ARQL - Yahoo! Finance NASDAQ View Institutional Holdings for ARQL - NASDAQ


Stock Charts

FinViz View ARQL Stock Insight & Charts - FinViz.com StockCharts View ARQL Investment Charts - StockCharts.com
BarChart View ARQL Stock Overview & Charts - BarChart Trading View View ARQL User Generated Charts - Trading View


Latest Financial News for ARQL

Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China
Posted on Friday February 09, 2018

Stock Monitor: Regeneron Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If you ...


ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018
Posted on Thursday February 08, 2018

ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Leerink Partners 7th Annual Global Healthcare Conference on February 15th, 2018, at 9:00 a.m.


BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China
Posted on Wednesday February 07, 2018

Feb 7 (Reuters) - Arqule Inc: * ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA * ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL ...


Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
Posted on Wednesday February 07, 2018

Roivant Sciences and ArQule, Inc. today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR inhibitor, in Greater China.


ArQule: Several Ways To Win Here
Seeking Alpha - Nov 2, 2017
The FDA granted Rare Pediatric Disease Designation to drug candidate miransertib (ARQ 092) for the treatment of Proteus syndrome, and they could receive a priority review voucher if approved.

Arqule: Updates After 3Q Results
Seeking Alpha - Nov 9, 2017
Shares have climbed slightly since my initial article, where I overcame my bias against this ¨penny stock¨ and discovered what could be a promising 2018 story.

$-0.09 EPS Expected for ArQule, Inc. (ARQL)
Reurope - 10 hours ago
Analysts expect ArQule, Inc. (NASDAQ:ARQL) to report $-0.09 EPS on March, 6.They anticipate $0.01 EPS change or 10.00 % from last quarter's $-0.1 EPS.

Cheap Stock Alert on ArQule, Inc. (NASDAQ:ARQL)
Collins Courier - 4 hours ago
Based on recent analysis, ArQule, Inc. (NASDAQ:ARQL) shares have been seen trading -13.13% off of the 50-day peak and 35.43% away from the 50-day bottom.
Brokerages Anticipate ArQule, Inc. (ARQL) to Post -$0.09 EPS - registrarjournal.com

Enter a stock symbol to view the stock details.